Yiling's 13 innovative traditional Chinese medicines are deeply cultivated in the cardiovascular and cerebrovascular, cold and respiratory markets

As a leading enterprise in traditional Chinese medicine innovation, Yiling Pharmaceutical has won 3 innovative traditional Chinese medicines in the past two years, and has accumulated 13 innovative patented traditional Chinese medicines
.
The company continues to increase investment in research and development, and its research and development expenses are already in a leading position in the traditional Chinese medicine industry, and it is actively deploying in the field of chemical medicine
.
At present, the company has 8 innovative drugs under development, 4 innovative traditional Chinese medicine drugs and 4 innovative chemical drugs.
Phase III clinical trials have been carried out for Class 1 new drug non-steroidal analgesic drug Aniprofen Injection
.
The process of internationalization has been accelerated, a variety of Chinese patent medicines are widely used in many countries around the world, and 15 ANDA products have been approved by the US FDA
.
13 Innovative Traditional Chinese Medicine Screens! Deeply cultivating the cardiovascular and cerebrovascular, cold and respiratory markets In the beginning of 2022, the first innovative drug approved for marketing has fallen into the field of traditional Chinese medicine
.
During the five-year period from 2017 to 2021, a total of 20 new Chinese medicines have been approved for marketing in China.
In 2021 alone, 12 new Chinese medicines have been approved
.
Among them, Yiling Pharmaceutical has won a total of 3 new Chinese medicine drugs, including Lianhua Qingke Tablets approved in 2020, Yishen Yangxin Anshen Tablets and Jieyu Chufan Capsules approved in 2021
.
Yishen Yangxin Anshen Tablet is used for insomnia.
It is a new traditional Chinese medicine compound preparation developed by Yiling Pharmaceutical Co.
, Ltd.
based on the theory of Zhonghua Tongluo Yangzi Jing to guide the pathogenesis and treatment of insomnia, and on the basis of clinical experience
.
Jieyu Chufan Capsule is an innovative traditional Chinese medicine drug independently developed by the company on the basis of clinical experience.
It is used for mild to moderate depression
.
In recent years, Yiling Pharmaceutical has been actively deploying drugs in the field of nervous system, and the approval of two new drugs is expected to bring new growth points to the company's performance
.
As a leading enterprise in scientific and technological innovation of traditional Chinese medicine in China, Yiling Pharmaceutical currently has 13 innovative patented new drugs, covering cardiovascular and cerebrovascular diseases, respiratory diseases, diabetes, tumors, nerves, urinary and other diseases with high incidence and large market dosage
.
The three new traditional Chinese medicines approved in the past two years, Lianhua Qingke Tablets, Yishen Yangxin Anshen Tablets and Jieyu Chufan Capsules, are all deployed in areas where clinical needs are not met.

.
Sources of the main innovative patented traditional Chinese medicines of Yiling Pharmaceutical: Among the 13 innovative patented new drugs in the Minet.
com database, Tongxinluo Capsules/Tablets, Shensong Yangxin Capsules, Qili Qiangxin Capsules, Lianhua Qingwen Capsules/Granules/Tablets, Jinlida Granules, Yangzhengxiaoji Capsules, Xia Liqi Capsules and Lianhua Qingke Tablets have entered the 2021 National Medical Insurance Catalogue, Tongxinluo Capsules, Shensong Yangxin Capsules, Lianhua Qingwen Capsules/Granules, Qili Qiangxin Capsules and Jinlida Granules entered the 2018 National Essential Drug List
.
In the field of drug use for respiratory diseases, Yiling Pharmaceutical has deployed innovative patented traditional Chinese medicines such as Lianhua Qingwen capsules/granules/tablets and Lianhua Qingke tablets
.
Since its entry into the market in 2003, Lianhua Qingwen has been listed in the diagnosis and treatment plan for the prevention and treatment of infectious diseases such as influenza A, influenza B, new coronary pneumonia, and Middle East respiratory syndrome by the National Health Commission, the Administration of Traditional Chinese Medicine and other departments for 27 consecutive times.

.
After years of hard work and development, Lianhua Qingwen Granules and Lianhua Qingwen Capsules have become the leading brands in the Chinese patent medicine market for colds
.
According to data from Minet.
com, in 2020, the sales of Lianhua Qingwen, a terminal in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions), exceeded 2 billion yuan, a year-on-year increase of 85.
29%; Its sales in the first half of 2019 have exceeded the full year of 2019, an increase of 31.
61% over the same period last year
.
In the field of cardiovascular and cerebrovascular diseases, Yiling Pharmaceutical has deployed three innovative patented traditional Chinese medicines: Tongxinluo Capsule, Shensong Yangxin Capsule and Qili Qiangxin Capsule.
The treatment scope covers the most common ischemia in cardiovascular and cerebrovascular diseases.
Cardiovascular and cerebrovascular disease, arrhythmia, heart failure three indications
.
In recent years, the market of Tongxinluo Capsules, Shensong Yangxin Capsules and Qili Qiangxin Capsules has continued to rise, and they have become the leading products in the domestic oral drug market for cardiovascular diseases
.
According to data from Minet.
com, the sales of Tongxinluo Capsules in public medical institutions in China will exceed 2 billion yuan in 2020, and the sales in the first half of 2021 will increase by 22.
16% year-on-year; the sales of Shensong Yangxin Capsules in 2020 will be close to 2 billion yuan; The annual sales of Qiangxin Capsules have exceeded 500 million yuan, with a year-on-year increase of 51.
22% in the first half of 2021
.
At present, Yiling Pharmaceutical's cardiovascular and cerebrovascular and cold respiratory products are already in a leading position in the market
.
It is worth mentioning that the drugs for cardiovascular and cerebrovascular diseases and the drugs for respiratory diseases are the first and second best-selling categories in the terminal Chinese patent medicine market of public medical institutions in China
.
R&D expenses are increasing rapidly! Eight innovative drugs are on the way.
In recent years, Yiling Pharmaceutical has continued to increase investment in research and development, and constantly improve its product array, and its research and development expenses have taken the leading position in the traditional Chinese medicine industry
.
In 2020, Yiling Pharmaceutical's research and development expenses were 654 million yuan, a year-on-year increase of 67.
47%; in the first three quarters of 2021, the company's research and development expenses were 538 million yuan, a year-on-year increase of 37.
96%
.
Yiling Pharmaceutical's R&D expenses (unit: 100 million yuan) Source: Company
announcement At present, Yiling Pharmaceutical has 8 innovative drugs under development, 4 innovative Chinese medicine drugs and 4 innovative chemical drugs
.
In terms of registration classification, there are 6 category 1 innovative drugs and 3 original category 6 new drugs
.
Yiling Pharmaceutical's main sources of innovative drugs under research: The Minet database is in the Chinese medicine sector.
Yiling Pharmaceutical focuses on the advantages and characteristics of traditional Chinese medicine treatment fields such as cardiovascular and cerebrovascular, respiratory, digestive, pediatrics, etc.
, and strengthens the theory of traditional Chinese medicine, human experience, The "three-in-one" Chinese medicine registration review evidence system for clinical trials has been established, continuously enriching the research and development array of Chinese medicine varieties, and expanding the therapeutic field of marketed varieties
.
The Class 1 Chinese medicine innovative drug Xiaoer Lianhua Qinggan Granules has launched Phase II clinical trials in November 2021, which will open up new markets for the company in the fields of respiratory and pediatrics
.
In the chemical medicine sector, Yiling Pharmaceutical has 4 Class 1 innovative drugs that have entered the clinical research stage
.
Among them, innovative drugs such as the anti-Parkinson's disease drug fennomide tablets, the anti-tumor drug XY0206 tablets, and the antithrombotic drug XY03-EA tablets are in phase I clinical stage, and the non-steroidal analgesic drug aniprofen injection is in phase III clinical stage
.
According to data from Minet.
com, in 2020, the sales of terminal non-steroidal anti-inflammatory and anti-rheumatic drugs in China's public medical institutions exceeded 15 billion yuan
.
Win 15 ANDA products! Over-evaluation of 10 varieties As domestic pharmaceutical companies set off "going to the sea", Yiling Pharmaceutical has also continued to accelerate the process of internationalization
.
The company's Lianhua Qingwen has been approved for listing in more than 20 countries and regions including Brazil, the Philippines, Indonesia and Canada; the innovative patented traditional Chinese medicine Tongxinluo Capsule, Shensong Yangxin Capsule and Qili Qiangxin Capsule are also widely used in many countries and regions around the world.
countries
.
In terms of chemical drugs, Yiling Pharmaceutical has 15 ANDA products approved by the US FDA, including celecoxib capsules, sildenafil citrate tablets, amlodipine besylate tablets, paroxetine tablets, anastrozole Tablets, Valacyclovir Tablets and other heavy products
.
From the perspective of therapeutic areas, there are 4 antihypertensive drugs, 3 antiviral drugs, and 2 antitumor drugs
.
In terms of consistency evaluation, Yiling Pharmaceutical has passed/deemed to pass the consistency evaluation of 10 varieties, focusing on cardiovascular system drugs (3), systemic anti-infective drugs (3), digestive system and metabolites (2).
a)
.
It is not difficult to find that, no matter in the field of traditional Chinese medicine or chemical medicine, cardiovascular system drugs are an important field of layout of Yiling Pharmaceutical
.
Yiling Pharmaceutical passed/deemed passed Consistency evaluation Drug sources: Metformin hydrochloride tablets, captopril tablets, ciprofloxacin hydrochloride tablets, tartaric acid among the 10 reviewed varieties in the MED2.
0 China Drug Evaluation Database of Minet.
com Metoprolol tablets and other 4 varieties won the bid for national centralized procurement, and the sales of metformin and ciprofloxacin ushered in a substantial increase
.
According to data from Minet.
com, in 2020, the sales of metformin hydrochloride tablets of Yiling Pharmaceutical, a public medical institution in China, increased by 945.
95% year-on-year, and in the first half of 2021, its sales increased by 14,250% year-on-year.

.
Currently, Yiling Pharmaceuticals has four additional applications for consistency evaluation, including Dextromethorphan Hydrobromide Tablets, Tinidazole Tablets, Ranitidine Hydrochloride Capsules, and Gliquidone Tablets, which are under review and are expected to be reviewed this year; Four varieties, including Cubitril-Valsartan Sodium Tablets, Celecoxib Capsules, Felodipine Sustained-Release Tablets, and Anastrozole Tablets, are under review as Class 4 imitations
.
Among them, sacubitril and valsartan sodium tablets have not been approved for the first imitation in China
.
Data source: Minet database, company announcement Note: The statistics are as of January 16.
If there are any omissions, please correct me!